ZBIO Insider Trading Activity and SEC Form 4 Filings
ZBIO insider trading summary
Over the past 12 months, insiders at Zenas BioPharma, Inc. (ZBIO) reported 15 open-market purchases worth $19.3M by 6 insiders and no sales on SEC Form 4. Net insider buying was $19.3M.
Latest ZBIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 18, 2026 | Leon O Moulder Jr | Chief Executive Officer | Buy | $1.0M (60,000 @ $16.88) |
| Apr 29, 2026 | Leon O Moulder Jr | Chief Executive Officer | Buy | $617K (35,000 @ $17.62) |
| Apr 28, 2026 | Leon O Moulder Jr | Chief Executive Officer | Buy | $451K (25,000 @ $18.02) |
| Mar 31, 2026 | Fairmount Funds Management LLC | Director | Buy | $3.0M (150,000 @ $20.00) |
| Mar 31, 2026 | Hongbo Lu | Director | Buy | $70K (3,768 @ $18.63) |
| Mar 31, 2026 | Peter Evan Harwin | Director | Buy | $3.0M (150,000 @ $20.00) |
| Mar 31, 2026 | Hongbo Lu | Director | Buy | $1.5M (75,000 @ $20.00) |
| Mar 31, 2026 | Fairmount Healthcare Fund II L.P. | Director | Buy | $3.0M (150,000 @ $20.00) |
| Mar 31, 2026 | Leon O Moulder Jr | Chief Executive Officer | Buy | $657K (34,000 @ $19.31) |
| Mar 31, 2026 | Tomas Kiselak | Director | Buy | $3.0M (150,000 @ $20.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.